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Vaccination with Bacille Calmette–Gue´rin (BCG) is given at birth to protect against tubercu-
losis (TB) in Pakistan. The country ranks 6th amongst high-burden countries worldwide
and has an incidence of 231/100,000 population. This was a cross-sectional multi-center
hospital-based study. TB patients (n = 218) with pulmonary (PTB, n = 120) or extrapulmo-
nary (ETB, 98) were recruited, and the presence of a BCG vaccination scar was documented.
Cases were further classified into minimal, moderate and advanced PTB or less severe (L-
ETB) or severe disseminated (D-ETB) disease. The association of age, gender and severity
of TB infections with BCG vaccination of the individual TB cases was investigated.
No difference was found of the BCG vaccination status of PTB and ETB cases, or in rela-
tion to age or gender. Patients under 29 years of age comprised the largest group. There
were more females with ETB than PTB. The largest group within ETB comprised those with
tuberculous lymphadenitis (LNTB, 39%). A significantly greater number of LNTB cases had
received BCG vaccinations than had those with pleural (unilateral) TB (p = 0.004), and tuber-
culous meningitis (p = 0.027) groups. Also, there were more immunized patients with pul-
monary as compared with pleural disease (p = 0.001).
LNTB represents localized granulomatous disease and the observation of higher vaccina-
tion rates in this group suggests that BCG has protected against more severe forms of TB in
this high-burden region.
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There were approximately 8.8 million cases of tuberculosis
(TB) in 2010, mostly in the 22 high-burden countries where
Pakistan ranks 6th with 34/100,000 deaths reported as a result
of TB in 2011 and with an incidence of 231/100,000 [1].
Pakistan has a low incidence of HIV infection, and the
incidence rate of TB in HIV-positive individuals is less than-African Society for Myco
ent of Pathology and Micr
Hasan).(PTB) with 18% as extrapulmonary (ETB) disease [1].
Vaccination with Mycobacterium bovis Bacille Calmette–
Gue´rin (BCG) strain affords protection against TB in children,
especially against the development of severe forms, such as,
miliary TB and tuberculous meningitis [2–4]. In adults, BCG
vaccination is thought to reduce the risk of TB, but there arebacteriology. All rights reserved.
obiology, The Aga Khan University, Karachi, Pakistan. Tel.: +92 21
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[5,6].
The BCG vaccination program was initiated in Pakistan in
1949 [7]. BCG is administered at birth or in the first month
after birth and has been part of the Extended Program of
Immunization (EPI) program since 1970 [8,9]. BCG coverage
is estimated to vary between 63% and 86% in children aged
12–23 months depending on the provincial region of their res-
idence [10]. A national health survey of Pakistan revealed that
only 21% of mothers were able to locate the vaccination cards
of their children aged less than 23 months [10]. Due to limita-
tions in obtaining physical records of vaccination records
amongst participants, assessment of prior vaccination has
in most cases been based on the evaluation of a BCG scar
and on verbal examination.
There is limited data as to the rates of TB in vaccinated
and unvaccinated children and adults in Pakistan. A study
of 100 cases of TB in children under 15 years of age showed
that the majority were vaccinated (76%); however, amongst
abdominal TB cases, there was a larger proportion of unvacci-
nated as compared with vaccinated individuals suggesting
that vaccination may have some beneficial effect in protec-
tion against disseminated extrapulmonary TB [11]. In another
study, in 100 pediatric cases of tuberculous meningitis, it was
observed that the majority of patients were vaccinated; how-
ever, there was a greater preponderance of tuberculomas
amongst children who had not received the BCG vaccination
[12]. In a recent study of 1000 cases of adult pulmonary TB,
the rates of BCG vaccination were found to be 41% [13]. Thus
far, no study has addressed the rates of BCG vaccination in
Pakistani adults with respect to the severity of disease. This
study investigated the association between the BCG vaccina-
tion in adult patients with pulmonary and extrapulmonary
TB in relation to the severity of disease in each group.Materials and methods
Study subjects
This was a cross-sectional observational study conducted be-
tween the period 2005 and 2009. The study was approved by
the Ethical Review committees of The Aga Khan University
Hospital and OJHA Institute for Chest Diseases, DOW Univer-
sity for Health Sciences, Karachi. Written informed consent
was taken from each patient. A total of 218 patients were
recruited from The Aga Khan University Hospital; Indus
Hospital; OJHA Institute for Chest Diseases; DUHS University
of Health Sciences; and the Orangi Urban Health Center,
Karachi. A clinical history was taken from the patients, and
those with chronic viral diseases such as hepatitis virus B
and hepatitis virus C were excluded from the study. None of
the patients had any history of human immunodeficiency
virus (HIV) infection. Inclusion criteria were: patients with a
confirmed TB diagnosis who had not received anti-tubercu-
lous therapy (ATT); male or female; unrelated study subjects.
Exclusion criteria were: pregnancy; co-morbid conditions
compromising the immune system (such as diabetes melli-
tus, chronic renal failure, chronic liver disease or corticoste-
roid therapy) and patients with relapsed TB. Patients wereaged 15 years and above except for two patients who were
13 years and three who were 14 years of age.
Patients were classified as pulmonary TB (PTB) or extrapul-
monary TB (ETB) as per WHO guidelines for treatment of TB
[14]. PTB patients were diagnosed by clinical examination,
chest X-ray, sputum acid-fast bacillus (AFB) microscopy and/
or AFB culture. Severity of PTB was classified as moderately
advanced (PTB-mod) or far advanced (PTB-adv) PTB using a
modified classification of the National Tuberculosis Associa-
tion of the USA based on extent of lung tissue involvement
[15]. Severity of ETB was assessed by WHO guidelines for clin-
ical management of TB [14], according to which cases with
tuberculous lymphadenopathy and unilateral pleural effusion
were classified as less-severe ETB (L-ETB) and spinal, abdom-
inal, ovarian and bilateral pleural effusion TB were classified
as severe disseminated ETB (D-ETB). The diagnostic criteria
used for each patient are provided in Table 1.
BCG strain
The Danish BCG strain 1331 (Copenhagen, State Serum Insti-
tute) was used in Pakistan up until the year 2007 [9]; therefore,
this is the vaccine that would have been used for the study
participants who were all born prior to this date.
Evaluation of BCG scar
The presence or absence of the vaccination was evaluated
using the presence of a scar as proxy for BCG vaccination.
The presence of a BCG scar was examined in the deltoid re-
gion. A verbal history regarding vaccination was taken from
the patients.Statistical analysis
The presence or absence of a BCG scar in patient cases was
compared using a Chi-squared analysis. p values 6 0.05 were
considered to indicate significant differences between groups.
A statistical analysis was performed using the Social Sciences
Software Package version 11.0, USA.Results
Study population
The presence of a BCG vaccination scar was investigated in
218 TB patients comprising 120 cases of PTB and 98 cases of
ETB. The diagnostic criteria used to identify TB in each case
are listed in Table 1.
The number of male and female patients with PTB and ETB
were compared using Chi-squared analysis. It was found and
it was observed that in the ETB group there were more fe-
males than males (p = 0.043) (Table 2). While in the cases of
PTB, the proportion of each gender was comparable.
When rates of vaccination were compared between sub-
jects with PTB and ETB, they were found to be approximately
similar. Also, the proportion of vaccinated males and females
in PTB and ETB cases were similar.
Table 1 – Diagnostic criteria for tuberculosis patients in the study.
Site n Abscess Microscopy Radiology AFBC Histopathology
PTB 120 54/66 120/120 22/28 11/14
L-ETB
LNTB 38 1 4/10 7/29 3/9 34/34
Unilateral pleural 19 4/4 16/17 4/4 2/2
D-ETB
Spine 14 9 1/3 7/8 3/5 4/4
Abdominal 9 2/4 3/4 1/3 3/3
Meninges 10 2/3 5/5 2/5 2/2
Miliary 3 1/1 3/3 N/A 1/1
Ovarian 2 N/A 1/1 1/2 1/2
Bilateral pleural 2 1/1 2/2 1/1 1/1
Vulval 1 N/A N/A N/A 1/1
In each case, the numbers denote the number tested positive out of the total tested in each category. PTB, pulmonary TB; L-ETB, less severe
extrapulmonary TB; LNTB, tuberculous lymphadenitis; D-ETB, severe disseminated ETB.
Microscopy indicates the number of acid fast bacilli smear-positive cases; AFBC, AFB culture-positive cases; Histopathology, indicates those
cases where histological staining revealed granulomatous lesions suggestive of M. tuberculosis infection; Radiology, indicates cases which
showed a chest X-ray predictive of TB.
Table 2 – Demographic characteristics of tuberculosis patients.
Characteristic TB patients n (% of 218) PTB n (% of 120) ETB n (% of 98) p-Value
Gender
Male 101 (46.3) 63 (52.5) 38 (38.7) 0.043*
Female 117(53.6) 57 (47.5) 60 (61.2)
BCG scar (all cases)
Yes 112 (51.4) 56 (46.6) 56 (57.1) 0.124
BCG scar (male)
Yes 47 (21.5) 27 (22.5) 20 (20.4) 0.34
Age mean(±SD) 33.4(±16.2) 32.7(±15.7) 34(±16.7) 0.373
Age groups
13–29 122 (55.9) 69(57.5) 53(54.1) 0.68
30–44 39 (17.8) 19(15.8) 20(20.4)
P45 57 (26.1) 32(26.6) 25(25.5)
Contact exposure
Yes 74 (33.9) 40 (33.3) 34 (34.7) 0.871
Previous history of TB
Yes 17 (7.8) 12 (10) 5 (95.1) 0.153
A significant difference between groups is indicated by ‘*’ using Chi-squared test analysis.
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patients with tuberculosis
When stratified into different age groups, it was observed that
the patients were predominantly in the youngest age group of
13–29 years. Overall, TB patients had a median age of
33.4 years and 51% of them had received the BCG vaccination
(Table 2). Next, the BCG vaccination was assessed in patients
stratified into different age groups. It was observed that there
were a higher number of BCG vaccines in the 30–44 year age
group as compared with those who were aged 13–29 years,
(p = 0.037, Fig. 1).
When gender differences were considered, it was observed
that the numbers of male and female TB patients in each of
the three age groups was comparable (data not shown). Therewas no difference between the numbers of males and females
who had received BCG vaccinations across the age groups
studied (data not shown).
Relationship of BCG vaccination with disease site and severity
of TB
In order to examine the relationship between the severity of
pulmonary and extrapulmonary disease and the BCG vaccina-
tion status of the patients, each group was studied separately
and divided based on the clinical severity of TB. PTB was clas-
sified into minimal, moderate and advanced disease. No dif-
ferences were observed between the proportions of
vaccinated individuals with any of these PTB sub-groups (Ta-
ble 3). ETB patients were classified into less severe localized
Fig. 1 – Frequency of BCG vaccination according to age of
patients. The graphs depict the percentage of patients with
tuberculosis who had a BCG scar (present, shaded bar) and
in those individuals where there was no BCG scar (absent,
clear bar) according to the different age groups of patients;
n = 122, aged 13–29 years; n = 39, aged 30–44 years and
n = 57, aged 45 years and over. ‘*’ denotes a significantly
higher value p 6 0.05 between vaccinated individuals in the
groups as analyzed by Chi squared test.
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comprised a majority of patients with tuberculous lymphade-
nitis (LNTB) and unilateral-pleural TB. Overall, LNTB cases
comprised 38.8% of all TB cases and 67% of L-ETB cases.
When gender was considered, the number of males and
females in the L-ETB and D-ETB group was found to be com-
parable (Table 3). However, the number of female patientsTable 3 – BCG vaccination characteristics according to site of TB
Site of TB Severity n (%) BCG scar
present n (%
Pulmonary 103 (51.2) 56 (54.4)
Minimal 15 (14.6) 5 (33.3)
Moderate 65 (63.1) 37 (56.9)
Advanced 23 (22.3) 8 (34.8)
Extrapulmonary 98 (48.8) 56 (57.1)
L-ETB 57 (58.2) 36 (63.2)
Pleural (unilateral) 19 (19.4) 7 (36.8)
Lymph Node 38 (38.8) 29 (76.3)
D-ETB 41 (41.8) 20 (48.8)
Abdominal 9 (9.2) 5 (55.5)
Meningitis 10 (10.2) 4 (40)
Spinal 14 (14.3) 7 (50)
Miliary 3 (301) 1 (33.3)
Pleural (bilateral) 2 (2.0) 1 (50)
Vulval 1 (1.0) 1 (100)
Ovarian 2 (2.0) 1 (50)
Information regarding extent of disease was not available for 17 PTB cas
L-ETB, less severe extrapulmonary TB; D-ETB, severe disseminated extra
extrapulmonary groups was compared using Chi squared analysis. A s
between groups using Chi-squared test analysis. NS; indicates no signifiwith D-ETB (n = 27) was approximately twice the number of
male patients in the group (n = 14).
This study also investigated the possibility of any relation-
ship between gender and vaccination in the sub-groups of TB
patients and found no such correlation. It was observed that
there was no gender difference amongst the TB cases as to
who had received BCG vaccination.
The number of individuals with BCG scars within each
class of TB patients was further compared. A significantly
greater proportion of patients with PTB were vaccinated as
compared with those who had pleural TB (p = 0.001). Also, a
greater proportion of individuals with BCG scars were ob-
served in the LNTB group as compared with those with pleu-
ral TB (p = 0.004) and D-ETB (p = 0.012) (Fig. 2).
Within the D-ETB group, the numbers of patients with TB
at different sites were too few to be analyzed separately and
were therefore pooled for further comparisons.
Discussion
In this study, it was observed that 41% of adults had received
the BCG vaccination as assessed by the presence of a BCG
scar. This proportion matches the percentage of 41% BCG vac-
cination in adults observed in another recent study from Paki-
stan [16].
The highest number of TB patients were aged 13–29 years
and there was an equivalent number of vaccinated and
unvaccinated individuals in this group, which may correlate
with the 50% or so rates of BCG protection that have been
shown in meta-analyses of vaccination studies [5]. It was ob-
served that there was a higher proportion of vaccinated than
unvaccinated individuals in groups aged 30–44 years as com-
pared with the former age group. There is no discerniblein patients.
)
p Value Male,
female n
BCG scar present p Value
Male n (%) Female n (%)
0.084 56, 47 26 (46.2) 29 (61.7) NS
7, 8 2 (28.6) 3 (37.5) NS
36, 29 18 (50) 18 (62.1) NS
13, 10 4 (30.8) 4 (40) NS
38, 60 20 (20.4) 36 (36.7) NS
24, 33 13 (54.2) 23 (69.6) NS
0.004* 12, 7 5 (41.7) 2 (28.6) NS
12, 26 8 (66.6) 21 (80.8) NS
14, 27 7 (50) 13 (48.1) NS
4, 5 2 (50) 3 (60) NS
6, 4 3 (50) 1 (25) NS
2, 12 2 (100) 5 (41.7) NS
2, 1 0 1 (100) NS
0, 2 0 1 (50) NS
0, 1 0 1 (100) NS
0, 2 0 1 (50) NS
es and these have been excluded from this table.
pulmonary TB. The presence of a BCG scar between pulmonary and
ignificant difference between groups is indicated by ‘*’, or p > 0.05
cant difference.
Fig. 2 – A larger proportion of patients with TB
lymphadenitis have received BCG vaccination. The graphs
depict the number of individuals where BCG scar was
present (shaded bar) and those where it was absent (clear
bar) according to the site of TB. PTB (n = 120), lymph node TB
(LNTB, n = 38), pleural n = 19 and severe disseminated ETB
(D-ETB, n = 41) cases. ‘*’ denotes a significant difference
p < 0.05 between the group as compared with LNTB. All
analyses were performed by Chi squared test analysis.
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the latter age group received the BCG vaccination during the
initiation phase of the EPI program in Pakistan in the 1970s
[8,9]. The patients were recruited from a private hospital
(AKU), a government-run hospital (OJHA) and a not-for-profit
charity hospital (Indus), so there should be no demographic
bias within the cases selected. Perhaps the difference be-
tween groups could be attributed to the different sizes of
the groups as there were 122 patients in the <29 year age
group and 39 patients in the 30–44 year age group.
It was noted that while there was no gender difference in
the number of patients with pulmonary disease, there were
more females than males with extrapulmonary TB. Particu-
larly, that in the D-ETB group there were twice as many fe-
males as male TB cases.
There was no difference found in the numbers of vacci-
nated and unvaccinated individuals with pulmonary disease.
This correlates with previous reports that have shown that
being BCG vaccinated is not associated with protection
against pulmonary disease [3,17,18]. No difference was found
in the numbers of individuals vaccinated based on their gen-
der. The higher rates of pulmonary as compared with extra-
pulmonary TB fit with global trends [19]. It is thought that
the BCG vaccination is most protective against severe dissem-
inated tuberculosis and especially meningeal disease in child-
hood [2,20].
However, there is limited information regarding the sever-
ity of TB amongst being BCG vaccinated and unvaccinated
individuals in adults. Amongst ETB patients, tuberculous
lymphadenitis was found to be the most common form as
has been reported previously [21,22]. Lymphadenitis is the
most restricted form of TB as it comprises local granulomas
with limited spread to other sites. Pleural disease although
localized has a stronger pro-inflammatory profile and is likely
to be clinically more acute [23]. The increased vaccination
rate observed in patients with lymphadenitis as comparedwith pulmonary, pleural and severe disseminated ETB is sug-
gestive of a protective effect of the BCG vaccination in this
group.
Although BCG vaccination may itself result in mycobacte-
rial disease, cases of BCG lymphadenitis occur within
24 months of vaccination [24]. As all the patients included
in the cohort were vaccinated at birth, therefore association
of lymphadenitis with BCG vaccination is unlikely.
This study has some limitations such that it relied upon
the patient’s own history for BCG vaccination and as such,
some could not be recruited as they did not know their own
vaccination status. In addition, the study relied upon the
presence of a BCG vaccination scar as a proxy for vaccination.
However, BCG scars may in some cases fade with time [25].
Also, as the persistence of scars has been shown to be lower
in individuals who were vaccinated as infants under 1 month
of age [26], therefore the rates of vaccination that were deter-
mined may be an underestimation of the study group.
Conclusions
Overall, the data of this study suggests that BCG vaccination
may protect against more severe forms of TB and also lead
to a preponderance of tuberculous lymphadenitis disease in
a high-burden region.Conflict of interest
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